This first-in-human clinical study aims to evaluate the safety and feasibility of locally delivered, allogeneic T cells (genetically edited with ARIH1 and BCL11b knockout, designated ABOUT T cells) in patients with glioblastoma multiforme (GBM). The engineered effector cells are delivered via localized administration to selectively target and eliminate residual GBM cells. ABOUT: ARIH1 and BCL11b knockOUT T cells.